Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Salzburg – page 2

285 clinical trials in Salzburg, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salzburg at a glance
285
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

285 trials in Salzburg

Open in trial search

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Pyoderma gangrenosum

Recruiting

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Partial seizures

Recruiting

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Colorectal cancer metastatic

Recruiting

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Colorectal cancer metastatic

Recruiting

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Salzburg

What the registry says about research in the country

01 Oncology Research

Comprehensive studies focusing on metastatic cancers and innovative treatment approaches, including trials investigating new therapies for prostate cancer, colorectal cancer, and bladder cancer.

  • Advanced cancer treatments
  • Immunotherapy combinations
  • Novel therapeutic agents

Multiple clinical trials evaluating targeted therapies and combination treatments for various stages of cancer progression.

02 Hematological Studies

Investigating breakthrough treatments for multiple myeloma and acute myeloid leukemia, with emphasis on innovative therapeutic combinations and targeted approaches.

  • Blood cancer therapies
  • Novel drug combinations
  • Treatment resistance studies

Focus on improving outcomes for patients with various blood disorders through advanced therapeutic strategies.

03 Chronic Disease Management

Research initiatives addressing cardiovascular disease, Crohn's disease, and Alzheimer's disease, exploring new treatment modalities and therapeutic approaches.

  • Inflammatory conditions
  • Cardiovascular health
  • Neurological disorders

Comprehensive studies aimed at developing more effective treatments for chronic conditions affecting quality of life.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.